New Data Shows Biodesix Blood Test Reliably Detects Additional Mutations in Patients with NSCLC BOULDER, Colo., April 18, 2018 (GLOBE NEWSWIRE) -- Biodesix®, Inc. is presenting new data today demonstrating the ability of the company’s droplet digital PCR (ddPCR™)-based platform to reliably...

Cyclacel’s CYC065 CDK Inhibitor Demonstrates Synergy With Venetoclax By Dual Targeting Of Chronic Lymphocytic Leukemia BERKELEY HEIGHTS, N.J., April 17, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting BERKELEY HEIGHTS, N.J., April 16, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...

Biodesix Announces Data To Be Presented at AACR Annual Meeting 2018 BOULDER, Colo., April 05, 2018 (GLOBE NEWSWIRE) -- Biodesix®, Inc. will present new data confirming the ability of the company’s droplet digital PCR (ddPCR™)-based platform to reliably detect key...

Phase 1 Clinical Data With Cyclacel’s CYC065 CDK Inhibitor Have Been Selected for Oral Presentation at AACR 2018 Annual Meeting BERKELEY HEIGHTS, N.J., March 15, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company"), a biopharmaceutical company developing oral...